Stockscreener 앱 받기
0.00%
전일 마감가:
$4.24
열려 있는:
$4.3
하루 거래량:
2.55M
Relative Volume:
0.64
시가총액:
$442.41M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.5854
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
+5.47%
1개월 성능:
-15.71%
6개월 성능:
+1.44%
1년 성능:
-36.81%
1일 변동 폭
$4.17
$4.37
1주일 범위
$3.96
$4.40
52주 변동 폭
$2.90
$7.73
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.24 | 442.41M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Market Pulse: Can Altimmune Inc keep up with sector leadersOptions Play & Growth Focused Stock Reports - baoquankhu1.vn
RSI Check: Can Stran Company Inc Equity Warrant beat the S P 500Portfolio Risk Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Rally Mode: Is Altimmune Inc stock a good pick for beginners2025 Volume Leaders & Safe Entry Zone Tips - baoquankhu1.vn
Can Altimmune's Pemvidutide Follow In The Footsteps Of Rezdiffra And Wegovy In The MASH Landscape? - RTTNews
Dow Update: Will Altimmune Inc stock recover faster than peersJuly 2025 Chart Watch & Reliable Breakout Forecasts - moha.gov.vn
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Earnings Surprises & Advanced Technical Signal Analysis - Улправда
Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets - TipRanks
Wayne Pisano Increases Stake in Altimmune Inc with Recent Share Purchase - GuruFocus
Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 335% Upside In Biotech - DirectorsTalk Interviews
Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASHHas The Bull Case Changed? - Yahoo Finance
Can Altimmune Inc. stock sustain free cash flow growthJuly 2025 Volume & Momentum Based Trading Ideas - ulpravda.ru
Published on: 2026-01-09 03:53:26 - ulpravda.ru
Entry Recap: Will Altimmune Inc. stock split attract more investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Will Altimmune Inc. stock split attract more investorsPortfolio Return Summary & Fast Moving Market Watchlists - ulpravda.ru
Swing Trade: Why Altimmune Inc. stock remains on buy listsJuly 2025 Selloffs & Smart Allocation Stock Reports - ulpravda.ru
Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed? - simplywall.st
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - The Globe and Mail
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash - TradingView — Track All Markets
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Altimmune’s MASH drug - Investing.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - The Manila Times
FDA flags new liver disease drug for faster review after promising early data - Stock Titan
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug - Stocktwits
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Jerome Durso Buys Handful Of Shares In Altimmune - Yahoo Finance
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st
Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up - TipRanks
Altimmune announces CEO transition - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
Altimmune posts mid-stage trial data showing antifibrotic activity of lead asset in MASH - MSN
Insider Buying: John Gill Acquires 12,500 Shares of Altimmune In - GuruFocus
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune Director John Gill Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune stock soars over 10% premarket on positive mid-stage data for liver disease treatment drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Buying: Jerome Durso Acquires 12,500 Shares of Altimmune Inc (ALT) - GuruFocus
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jordt Raymond M | Chief Business Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
9,375 |
0 |
45,645 |
| Jorkasky Diane | Director |
Dec 29 '25 |
Buy |
3.80 |
527 |
2,003 |
527 |
| GILL JOHN | Director |
Dec 23 '25 |
Buy |
4.10 |
12,500 |
51,250 |
12,500 |
| Durso Jerome Benedict | Director |
Dec 22 '25 |
Buy |
4.13 |
12,500 |
51,569 |
12,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Nov 11 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
28,750 |
| Sohn Catherine A. | Director |
Mar 17 '25 |
Buy |
5.78 |
1,000 |
5,784 |
1,000 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
4.73%
0.92%
자본화:
|
볼륨(24시간):